Incidence of interstitial lung diseases in the south of Spain 1998–2000: The RENIA study

Lόpez-Campos, José Luís; Rodríguez-Becerra, Eulogio

doi:10.1023/b:ejep.0000017660.18541.83

Cited by 56 publications

(46 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the limitations discussed above, the IP IRs we identified in the general population were in the same range as those reported by the only two other population-based studies on this condition, conducted in New Mexico, USA, and Southern Spain (Coultas et al, 1994;Lopez-Campos and Rodriguez-Becerra, 2004). This provides confirmation for the methodological strength of our study.…”

Section: Discussionsupporting

confidence: 75%

Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study

et al. 2008

View full text Add to dashboard Cite

Chemotherapy and radiation therapy may increase risk for interstitial pneumonitis (IP) in breast cancer patients, but there are little current population-based data on IP incidence in these patients. We assessed population-based incidence rates (IRs) of IP among Danish breast cancer patients and compared these with IRs for the Danish general population. Through the Danish Cancer Registry, we identified all Danish breast cancer patients (n ¼ 35 823) diagnosed between 1994 and 2004. Treatment data were obtained from the Danish Breast Cancer Cooperation Group database, and data on IP, from the Danish National Registry of Patients. We computed IRs of IP among breast cancer patients and age-standardised incidence rate ratios (SIRs) comparing breast cancer patients with the general population. During follow-up, 28 breast cancer patients were registered with an IP diagnosis (IR ¼ 17.3 per 100 000 personyears (p-y) (95% confidence intervals (95% CI): 11.7 -24.6)). When follow-up was restricted to 1 year after the first breast cancer diagnosis, eight patients with IP were identified (IR ¼ 23.4 per 100 000 p-y (95% CI: 11.0 -44.1)). The SIR comparing breast cancer patients with the general population was 8.4 (95% CI: 5.7 -11.9). Thus, although IP is a rare adverse event among breast cancer patients, its risk is substantially higher than that in the general population.

show abstract

Section: Discussionsupporting

confidence: 75%

Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Han [24] (South Korea) (n = 358) Ohno [26] (Japan) (n = 545) Rufino [19] (Brazil) Fernandez Perez [30] (USA) (n = 24) Agabiti [14] (Italy) (n = 1752) Szafranski [32] (Poland) Musellim [37] (Turkey) (n = 408) Karakatsani [36] (Greece) (52) Lopez-Campos [38] (Spain) (n = 287) Xaubet [39] (Spain) (n = 197) Tinelli [40] (Italy)…”

Section: Resultsmentioning

confidence: 99%

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review

et al. 2015

View full text Add to dashboard Cite

As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. This study aims to systematically assess all available studies to investigate the global burden of disease.Medline and Embase databases were searched systematically for all population-based studies of incidence or mortality of idiopathic pulmonary fibrosis. Clinical case series and prevalence studies were excluded. The search was supplemented using the Google search engine, hand-searching of references and conference abstracts. Data were extracted independently by two authors using a pre-specified proforma, with assessment of methodological quality.34 studies were identified, providing data from 21 countries from 1968-2012. 28 studies reported incidence data and eight reported mortality data. In studies from the year 2000 onwards, we estimated a conservative incidence range of 3-9 cases per 100 000 per year for Europe and North America. Incidence was lower in East Asia and South America. The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary fibrosis is increasing worldwide and rates are coming together across countries. Current data suggest incidence is similar to that of conditions such as stomach, liver, testicular and cervical cancers. @ERSpublications Incidence of IPF varies worldwide but seems to be increasing to rates around 3-9 per 100 000 per year http://ow.ly/KSeMZ

show abstract

“…Proportions per 100,000 population ranged from 0.1 to 64 [14][15][16]. Available individual country prevalences were used for the UK [17], Israel [18], Iceland [19], Spain (pulmonary sarcoidosis only) [20], Greece [21], Switzerland [22], Japan [23] and the USA [24]. Extrapolations were made as follows: China and Vietnam were assumed to be similar to Singapore Chinese [25]; India, Pakistan and Bangladesh, to Singapore Indians [25]; Philippines, Thailand and Indonesia, to Singapore Malaysians [25]; Congo, Nigeria and Ethiopia, to UK black people [26]; Egypt and Iran, to Turkey [27]; and Russia, to Finland [23].…”

Section: Methodsmentioning

confidence: 99%

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Pleuvry²,

2012

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) may complicate pulmonary sarcoidosis. We re-estimated the global burden of sarcoidosis and the burden of CPA complicating sarcoidosis.We searched the literature and reference lists of retrieved papers to identify all published sarcoidosis incidence and prevalence data. We estimated the frequency of CPA from 11 papers relating to .3,000 patients with sarcoidosis to derive CPA patient numbers. We applied an annual attrition rate of 15% (range 10-25%) to estimate the global burden of CPA.We estimate that the annual incidence of sarcoidosis is 344,000 patients worldwide and the prevalence is ,1,238,000 cases, distributed as follows: 165,979 in Europe, 224,000 in the Americas, 492,892 in Africa, 80,023 in the Eastern Mediterranean, 41,660 in the West Pacific and 234,010 in Southeast Asia. CPA complicates sarcoidosis in 3-12% of cases. Using a 6% frequency, we estimate a global burden of 71,907 (range 35,954-143,815 (3-12%)) CPA cases complicating sarcoidosis, with 24% and 37% of cases estimated to be present in the Americas and Africa, because of the higher incidence of sarcoidosis in black people.As CPA responds to long-term antifungal therapy, which may prevent life-threatening haemoptysis, screening periodically for CPA in those with pulmonary sarcoidosis may be important, especially in patients requiring corticosteroid therapy.

show abstract

Incidence of interstitial lung diseases in the south of Spain 1998–2000: The RENIA study

Abstract: The study of the incidence of ILD depicts an intermediate situation from previous studies on the incidence and distribution of this group of diseases.

Cited by 56 publications

References 13 publications

Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study

Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Contact Info

Product

Resources

About